NeuBase Therapeutics, Inc entered into a Subscription and Investment Representation Agreement of Series A Preferred Stock, par value $0.0001 per share, for $1 per share for gross proceeds $1 on May 29, 2024. The Series A Preferred Stock is not convertible into shares of Common Stock or any other class or series of stock of the Company. The transaction includes participation from single investor.